KLCM Advisors Inc. Sells 288 Shares of Johnson & Johnson (NYSE:JNJ)

KLCM Advisors Inc. cut its position in Johnson & Johnson (NYSE:JNJ) by 3.9% in the 4th quarter, HoldingsChannel.com reports. The firm owned 7,166 shares of the company’s stock after selling 288 shares during the period. KLCM Advisors Inc.’s holdings in Johnson & Johnson were worth $1,123,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also added to or reduced their stakes in the company. DORCHESTER WEALTH MANAGEMENT Co boosted its stake in Johnson & Johnson by 0.6% in the 3rd quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 75,495 shares of the company’s stock valued at $11,758,000 after purchasing an additional 414 shares during the period. OneAscent Financial Services LLC lifted its position in shares of Johnson & Johnson by 82.8% during the 4th quarter. OneAscent Financial Services LLC now owns 9,838 shares of the company’s stock valued at $1,542,000 after acquiring an additional 4,457 shares during the period. TrueMark Investments LLC bought a new stake in shares of Johnson & Johnson during the 4th quarter valued at $1,458,000. RAM Investment Partners LLC lifted its position in shares of Johnson & Johnson by 4.5% during the 4th quarter. RAM Investment Partners LLC now owns 1,688 shares of the company’s stock valued at $265,000 after acquiring an additional 73 shares during the period. Finally, RFG Advisory LLC lifted its position in shares of Johnson & Johnson by 12.6% during the 3rd quarter. RFG Advisory LLC now owns 18,758 shares of the company’s stock valued at $2,921,000 after acquiring an additional 2,102 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Insider Activity

In other news, major shareholder & Johnson Johnson sold 3,725 shares of the firm’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the transaction, the insider now directly owns 4,099,575 shares in the company, valued at $105,810,030.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, EVP Jennifer L. Taubert sold 59,397 shares of the firm’s stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the completion of the transaction, the executive vice president now directly owns 141,416 shares in the company, valued at $22,099,078.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder & Johnson Johnson sold 3,725 shares of the firm’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the transaction, the insider now owns 4,099,575 shares of the company’s stock, valued at $105,810,030.75. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

JNJ has been the subject of a number of recent analyst reports. HSBC upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and upped their target price for the company from $169.00 to $170.00 in a research report on Thursday, April 18th. Raymond James upped their target price on Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a research report on Wednesday, January 3rd. Royal Bank of Canada cut their target price on Johnson & Johnson from $181.00 to $175.00 and set an “outperform” rating for the company in a research report on Wednesday, April 17th. Morgan Stanley lowered their price target on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a report on Wednesday, April 17th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a report on Monday, April 15th. Seven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $175.86.

Johnson & Johnson Price Performance

Shares of JNJ opened at $149.12 on Tuesday. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $175.97. The business has a 50-day simple moving average of $155.97 and a two-hundred day simple moving average of $155.57. The company has a quick ratio of 0.91, a current ratio of 1.16 and a debt-to-equity ratio of 0.38. The stock has a market cap of $359.35 billion, a PE ratio of 9.30, a PEG ratio of 2.44 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.64 by $0.07. Johnson & Johnson had a return on equity of 36.43% and a net margin of 45.26%. The business had revenue of $21.38 billion during the quarter, compared to analysts’ expectations of $21.39 billion. During the same quarter in the prior year, the firm earned $2.68 EPS. The business’s revenue for the quarter was up 2.3% compared to the same quarter last year. Analysts anticipate that Johnson & Johnson will post 10.65 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Tuesday, May 21st will be issued a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.33%. The ex-dividend date of this dividend is Monday, May 20th. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s dividend payout ratio is presently 29.68%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.